Contrary to popular belief and despite the expenditure of massive amounts of research funds, there has been no improvement, since 1973, in the survival rates of patients with distant metastatic cancer. This sobering fact has led to attempts to develop more specific treatments by targeting hormone receptors expressed by the cancer cells and to develop drugs that are able to seek out and destroy distant and dormant metastatic cells. Remarkable success has been attained in developing drugs that target LH/chorionic gonadotropin, LHRH (GnRH), and estrogen receptors expressed by prostate, breast, ovarian, and testicular cancer cells.
Each of the three papers included in the minireview makes a significant contribution to the targeting of effective drugs to these cancers and their metastases. In the first paper, Attila Nagy and Andrew Schally describe their development of two chemotherapeutic agents, A-152 and AN-207, designed to target LHRH receptors expressed by breast, ovarian, prostate, and endometrial cancers. These compounds consist of highly active derivatives of doxorubicin covalently linked to the carrier peptide [D- In the second paper, Carola Leuschner and William Hansel describe the development of three compounds, Hecate-␤CG, Phor14-␤CG, and Phor21-␤CG(ala), which target and destroy cancer cells that express LH/CG receptors. These lytic peptides (Phor14, Phor21, and Hecate) disrupt cell membranes, and when targeted to cancer cells by conjugation with a 15-amino acid segment of the ␤ chain of hCG, are remarkably effective in destroying human breast, prostate, ovarian, and testicular cancer xenografts in the nude mouse. These lytic peptide-␤CG compounds are also very effective in destroying metastatic and dormant prostate cancer cells in lymph nodes, bones, lungs, and other organs.
In the third paper, Otabek Imamov, Gil-Jin Shim, Margaret Warner, and Jan-Å ke Gustafsson review the roles of the two estrogen receptors (ER␣ and ER␤) in several human diseases, including prostatic hyperplasia and adenocarcinoma. They have developed the concept that the androgen receptor causes proliferation of prostatic epithelium, while ER␤ suppresses proliferation and promotes differentiation; 3␤ androstanediol is the natural ligand for ER␤ and promotes differentiation of prostate epithelium. ER␤ agonists that inhibit prostate growth may have a major impact on treatment of prostate cancers.
These three reviews show that reproductive hormone receptors on a number of cancer cells can be targeted by constructs that destroy both the primary tumors and their metastases. Collectively, these papers establish the basis for a new approach to cancer chemotherapy.
